Psychedelics are once again hinting at a major reversal. With Cannabis stocks essentially confirming reversal breakouts, will psychedelics be able to join? It comes down to that catalyst. Will…
Filament Health
Two for Two $23.066M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has been issued a second patent by the Canadian Intellectual Property Office (CIPO) for the…
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
Filament Health (FH.NE) has released two new press releases since the last time I covered the company back in mid January 2022. Filament Health Corp. operates as a natural psychedelic…
Filament Health (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial using PEX010, the Company’s botanical psilocybin drug candidate. Cybin Therapeutics…
A Change In Stance Filament Health Corp (FH.NE) announced today that Psilo Scientific Ltd., the Company’s wholly-owned subsidiary, has joined Health Canada’s list of licensed psilocybin producers. No, we…
Filament Health Corp. operates as a natural psychedelic drug discovery and extraction technology company. It propagates psychedelic plants; conducts genetic research; performs extraction procedures; runs in-house trials; and distributes IP…
I’ll admit that I’m beginning to have my suspicions about the psychedelic sector. The question I’ve started asking when I look at a new psychedelics company is where’s the…
$41.189M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has received approval from Health Canada for a Phase 2 clinical trial utilizing the Company’s standardized natural psilocybin…